New vaccine shows promise as stronger weapon against both tuberculosis and leprosy
In many parts of the world, leprosy and tuberculosis live side-by-side. Worldwide there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic. The currently available century-old vaccine Bacille Calmette-Guerin, or BCG, provides only partial protection against both tuberculosis and leprosy, so a more potent vaccine is needed to combat both diseases. UCLA-led research may have found a stronger weapon against both diseases. In a study published in the September issue of the peer-reviewed journal Infection and Immunity, the researchers found that rBCG30, a rec...
Source: UCLA Newsroom: Health Sciences - August 19, 2014 Category: Universities & Medical Training Source Type: news

BCG-TB Vaccination May Be Delayed for HIV-Exposed Infants BCG-TB Vaccination May Be Delayed for HIV-Exposed Infants
A South African study has found no evidence suggesting that delayed BCG vaccination in HIV-exposed infants compromises immune responses to the vaccine. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2014 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Study: BCG prevents TB infection in children
New research published in the BMJ shows that the BCG vaccine may also protect against TB infections Hide related content:  Show related content read more (Source: Nursing in Practice)
Source: Nursing in Practice - August 7, 2014 Category: Nursing Authors: Lalah-Simone Springer Tags: Children ' s health Infections Editor s pick Latest News Source Type: news

BCG vaccine prevents TB infection in children
It has been widely accepted that BCG vaccine protects against the most severe forms of disease such as tuberculosis (TB) meningitis in children. This review of existing research indicates BCG vaccine can also protect against an individual becoming infected. (Source: NHS Networks)
Source: NHS Networks - August 7, 2014 Category: UK Health Authors: Maria Axford Source Type: news

Scissoring the lipids
A new strategy which enables molecules to be disconnected essentially anywhere, even remote from functionality, is described by researchers from the University of Bristol in Nature Chemistry today. The method is now being developed to explore the possibility of creating a tuberculosis (TB) vaccine. (Source: University of Bristol news)
Source: University of Bristol news - July 28, 2014 Category: Universities & Medical Training Tags: Research; Faculty of Science, Faculty of Science, School of Chemistry; Press Release Source Type: news

Progress in fight against tuberculosis
Leading immunologists express confidence that clear advances in the fight against tuberculosis are within reach. "The old BCG vaccine against tuberculosis primarily activates only helper cells. The trick with our new vaccine is to additionally activate the killer cells, which enables us to trigger an improved immune system response," one expert says. In addition to research into vaccines, innovative treatments are also being investigated which attempt to entice the bacteria out of their macrophage hiding places. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 30, 2014 Category: Science Source Type: news

Public health issues in tuberculosis: vaccination and immunisation
Anyone working in public health will tell you that there aren’t many ‘quick wins,’ but vaccination and immunisation just happen to be one of the few. Not only that, but alongside having a supply of clean water, these are the most important public health interventions. Hide related content:  Show related content read more (Source: Nursing in Practice)
Source: Nursing in Practice - April 8, 2014 Category: Nursing Authors: Lalah-Simone Springer Tags: Travel health Infections Source Type: news

Dartmouth and Aeras Join Forces to Conduct Study of New Tuberculosis Vaccine
Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - March 19, 2014 Category: Hospital Management Authors: derik.hertel at dartmouth.edu (Derik Hertel) Source Type: news

Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine
(The Geisel School of Medicine at Dartmouth) Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis, one of the world's deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of tuberculosis in a trial known as the DarDar Trial. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 19, 2014 Category: Global & Universal Source Type: news

Novel vaccine trial design aims to answer key TB questions
(Aeras) Aeras today announced the initiation of the first randomized, controlled tuberculosis vaccine trial designed to study prevention of Mycobacterium tuberculosis infection by vaccination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2014 Category: Global & Universal Source Type: news

January's top stories: NIBIO, Aeras and CREATE partner to advance development of new TB vaccines
NIBIO, Aeras and CREATE partner to advance development of new TB vaccines, while Bayer launches takeover offer for all shares of Algeta for €2.1bn. Pharmaceutical-technology.com wraps up the key headlines from January 2014. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 4, 2014 Category: Pharmaceuticals Source Type: news

NIBIO, Aeras and CREATE partner to advance development of new TB vaccines
Japan's National Institute of Biomedical Innovation (NIBIO), Aeras and Create Vaccine Company (CREATE) have entered into a collaboration agreement for the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 29, 2014 Category: Pharmaceuticals Source Type: news

Global collaboration forms to advance Japanese TB vaccine technology
(Aeras) Japan's National Institute of Biomedical Innovation, Aeras and Create Vaccine Company, Ltd. announce an agreement on the development of new mucosal tuberculosis vaccines based on the National Institute of Biomedical Innovation's human parainfluenza type-2 vector technology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 27, 2014 Category: Infectious Diseases Source Type: news

BCG vaccine more effective than previously thought
The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to study funded by the NIHR HTA Programme. Bacillus Calmette Guérin (BCG) vaccine is included in the childhood vaccination programme of many countries, and is the only licensed vaccine against tuberculosis (TB). However,... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - January 9, 2014 Category: American Health Source Type: news

BCG vaccine ‘more effective’ than thought
UK researchers have found the BCG vaccine to be more effective against the most common form of tuberculosis than previously thought. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - December 28, 2013 Category: Nursing Source Type: news